Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 8 of 8 for “"EML4-ALK"”.
-
Cost-utility analysis of EML4-ALK fusion testing followed by treatment with crizotinib in patients with Non-Small Cell Lung Cancer (NSCLC)
… by Pfizer, Inc. demonstrated that crizotinib (Xalkori, Pfizer, Inc.) offers significant improvement in clinical outcomes as a second line therapy for the treatment of EML4-ALK fusion–positive non-small-cell lung cancer (NSCLC). In 2013, the US Food and Drug Administration (FDA) approved …
-
NOVEL THERAPEUTIC STRATEGIES IN LUNG CANCERSTRONG BIOLOGICAL BIAS FOR ALK INTRON 19 BREAKPOINTS IN NON-SMALL LUNG CANCER
… therapy with tyrosine kinase inhibitors. EML4-ALK translocations are detected in 4-8 % of NSCLC and define a specific subtype of oncogene-driven lung cancer. While different EML4-ALK variants are defined by different breakpoints in the EML4 gene, most frequently located in intron 6 or 13, …
-
Dissecting mechanisms and consequences of oncogenic RTK fusion signaling
… optogenetics and live-cell imaging to find that EML4-ALK, an oncogenic fusion present in 5-7% of non-small cell lung cancers, suppress transmembrane RTK signaling by sequestering RTK adapter proteins including GRB2 and SOS1. Furthermore, ALK inhibition, while suppressing oncogenic signaling, …
-
A systems approach to uncovering the adaptive response of cancer to targeted therapies
… cell lines that we classify as either EGFR+ or EML4-ALK+. From both mass spectrometry data and growth assays, we identified an unintuitive boost in signaling and growth in response to low inhibitor concentrations, suggestive of a cellular mechanism that is adaptive to driver kinase inhibition. …
-
Discovery and Development of Predictive Biomarkers for the Personalization of Pemetrexed Therapy in Non-Small Cell Lung Cancer
… more frequent in sensitive lines, and EML4/ALK adenocarcinomas conferred sensitivity to pemetrexed, consistent with recent clinical findings. In order to test whether the in vitro pemetrexed response phenotypes could be recapitulated in vivo, doses from 26.6 mg/kg up to 1000 mg/kg …
-
Identification and functional characterisation of gene fusions in human cancer cell lines
… The discovery of gene fusions such as EML4-ALK in lung cancer and BCR-ABL1 in chronic myeloid leukaemia have already led to changes in clinical care. However, important questions remain about the role of gene fusions in promoting oncogenic phenotypes and their relevance in drug …
-
Procaspase-3 activation as a strategy to overcome resistance to targeted anticancer therapies
… in the MAPK pathway. Besides BRAFV600E, EGFR, ALK, ABL, and RAS are oncogenes that are frequently altered in this pathway. While many mutant oncogenes have been identified, only mutations or alterations to EGFR, ALK, and ABL kinases can be targeted clinically by specific kinase inhibitions to …
-
Studying the Transcriptional and Epigenetic Perturbations of Haematopathologies Expressing NPM1-ALK
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase involved in the development of the gut and nervous system, initially cloned from cases of T-cell lymphoma. ALK has been frequently implicated in diverse cancers through oncogenic translocations, mutations, chromosomal inversion, or amplification …